1. Biologics in severe asthma – a molecular perspective
   Laura Haidar et al, 2022, Alergologia CrossRef
2. Advances and Highlights of miRNAs in Asthma: Biomarkers for Diagnosis and Treatment
   Marta Gil-Martínez et al, 2023, International Journal of Molecular Sciences CrossRef
3. Utility of Kansas City Cardiomyopathy Questionnaire (KCCQ) in Assessing Quality of Life among Patients with Heart Failure Undergoing Exercise Training Rehabilitation: A Systematic Review
   Ilona Emoke Sukosd et al, 2024, Diseases CrossRef
4. Dupilumab pharmacokinetics and effect on type 2 biomarkers in children with moderate-to-severe asthma
   Daniel J. Jackson et al, 2023, Annals of Allergy, Asthma & Immunology CrossRef
5. Association between 25-hydroxy vitamin D and lung function (FEV1, FVC, FEV1/FVC) in children and adults with asthma: A systematic review
   Meryem Abi-Ayad et al, 2023, Lung India CrossRef
6. Differential drug response in pulmonary arterial hypertension: The potential for precision medicine
   Elise Miller et al, 2023, Pulmonary Circulation CrossRef
7. Patient characteristics and eligibility for biologics in severe asthma: Results from the Greek cohort of the RECOGNISE “real world” study
   Petros Bakakos et al, 2023, Respiratory Medicine CrossRef
8. Reserve Biologics for Chronic Rhinosinusitis with Nasal Polyps After Failed Sinus Surgery
   David Z. Allen et al, 2023, Current Otorhinolaryngology Reports CrossRef
9. Real-World clinical outcomes of asthma patients switched from reslizumab to mepolizumab or benralizumab
   Laura J. Walsh et al, 2023, Frontiers in Allergy CrossRef
10. Pulmonary Diseases in Older Patients: Understanding and Addressing the Challenges
    Pushpa Raj Joshi, 2024, Geriatrics CrossRef
11. Specific Therapy for T2 Asthma
    Diego Bagnasco et al, 2022, Journal of Personalized Medicine CrossRef